Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance

BACKGROUND: Resistance is almost inevitable and is still a major obstacle in epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Only limited relevant clinical studies evaluated the therapeutic effects by combing metformin and EGFR-TKIs in non-small cell lung cancer (NSC...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Transl Lung Cancer Res
Egile Nagusiak: Han, Ruoshuang, Jia, Yijun, Li, Xuefei, Zhao, Chao, Zhao, Sha, Liu, Sangtian, Liu, Yiwei, Chen, Donglai, Zhang, Qian, Liu, Xiaozhen, Shi, Jinpeng, Li, Jiayu, Zhou, Caicun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AME Publishing Company 2021
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8044488/
https://ncbi.nlm.nih.gov/pubmed/33889509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-1153
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak